Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acrobot Pursues Orthopedic Partners In Multiple Markets

This article was originally published in The Gray Sheet

Executive Summary

Acrobot is seeking a partner to help market its line of "intelligent surgical tools" in the U.S. orthopedic implant surgery market beginning in 2009

You may also be interested in...



People Briefs: Wright Medical; Reapplix APS; Sotera Wireless

Wright Medical Group appoints Kevin Cordell president, U.S. extremities; wound therapy patch developer Reapplix names CEO; Sotera Wireless taps senior VP, sales and marketing.

Acrobot/Corin

Corin Group will distribute Acrobot's Acrobot Navigation electromagnetic navigation system for hip resurfacing surgeries in the UK, Germany and Australia. Under the agreement announced May 27, Corin will buy the systems from Acrobot and market them alongside its Cormet hip resurfacing system.The agreement is London-based Acrobot's first commercial route-to-market agreement. Corin and Acrobot have been cooperating to adapt Acrobot's system for hip resurfacing since 2004, and at the end of 2007 Corin owned about 10% of the company. Acrobot's other partners include Biomet, Stanmore Implants and the Imperial College London

Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance

Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel